Polypharmacophoric agents
One aspect of the present invention relates to polypharmacophoric compounds. In certain embodiments, the polyphamacophore compounds comprise individual pharmacophore units selected from the group consisting of D-1 agonists, D-2 agonists, D-3 agonists, D-4 agonists, irreversible monoamine inhibitors, reversible monoamine inhibitors, monoamine transporter inhibitors, COMT inhibitors, MAO inhibitors, and dopamine transporter inhibitors. Moreover, the present invention also relates to combinatorial libraries of polypharmacophoric compounds. Another aspect of the present invention relates to the use of a polypharmacophoric compound in a method of treating a mammal in need thereof. For example, a polypharmacophoric compound of the present invention may be used in a method of treating a mammal afflicted with Alzheimer's Disease, Huntington's Disease, depression, attention deficit disorder, autism, obesity, or inflammation.
1 - 54 . (canceled)
55 . A polypharmacophore selected from the group consisting of:
56 . A polypharmacophore represented by formula (II):
wherein:
R 10 is selected from the group consisting of phenyl and substituted phenyl;
R 11 is selected from the group consisting of phenyl and substituted phenyl; and
X is selected from the group consisting of CH and N.
57 . The polypharrnacophore of claim 56 , wherein each of R 10 and R 11 is phenyl.
58 . The polypharmnacophore of claim 57 , wherein each of R 10 and R 11 is substituted phenyl.
59 . The polypharmnacophore of claim 58 , wherein said substituted phenyl is 4-fluorophenyl.
60 . A pharmaceutical composition comprising a polypharmacophore of claim 55 or 56 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable diluent or carrier.